BioCentury

7:00 AM GMT, Sep 29, 2008
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Venturing into ophthalmic space

Venturing into ophthalmic space

Company Type Date Raised Description
Alacrity Biosciences Debt 3/5/07 $8.5 Developing compounds to treat ocular surface diseases, glaucoma and retinal disease. Lead compound is ALTY-0501, a topical formulation of doxycycline that has completed a Phase II trial.
Alimera Sciences Series C 3/18/08 $30.0 Focused on diseases that affect the back of the eye (retina). Lead compound is Iluvien,

Read the full 761 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.